Se ha denunciado esta presentación.
Se está descargando tu SlideShare. ×

Applications of high-throughput sequencing (HTS) technologies in the pharma industry

Ad

Applications of high-throughput
sequencing (HTS) technologies in
the pharmaceutical industry
Enrico Ferrero, PhD
Computati...

Ad

The drug discovery pipeline
New medicine: $1 bn, 15 years
Applications of HTS technologies in the pharma industry
Enrico F...

Ad

Challenges in the pharma industry
Time and costs are increasing but success rate is declining
3Applications of HTS technol...

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Ad

Eche un vistazo a continuación

1 de 20 Anuncio
1 de 20 Anuncio

Más Contenido Relacionado

Presentaciones para usted (19)

Applications of high-throughput sequencing (HTS) technologies in the pharma industry

  1. 1. Applications of high-throughput sequencing (HTS) technologies in the pharmaceutical industry Enrico Ferrero, PhD Computational Biology @ GSK BioData World Congress 22.10.2015
  2. 2. The drug discovery pipeline New medicine: $1 bn, 15 years Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK 2
  3. 3. Challenges in the pharma industry Time and costs are increasing but success rate is declining 3Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  4. 4. 4 Computational Biology @ GSK Supporting the drug discovery pipeline Target Preclinical Clinical Launch Disease understanding Target discovery Drug MOA Indication mining Patient stratification Efficacy and safety Drug repositioning Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  5. 5. 5 Where can HTS technologies help more? Target Preclinical Clinical Launch Disease understanding Target discovery Drug MOA Indication mining Patient stratification Efficacy and safety Drug repositioning Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  6. 6. Genomics and high-throughput sequencing What HTS technologies do we use? Transcriptomics Epigenomics Regulomics RNA-seq ChIP-seq DNase-seq BS-seq
  7. 7. Disease understanding
  8. 8. Disease progression in rheumatoid arthritis RNA-seq + BS-seq  Part of the BTCURE research project, in collaboration with the Academisch Medisch Centrum (Amsterdam, NL).  Pilot study involving a small number of synovial biopsies from RA patients at different stages and degrees of severity.  Samples profiled by RNA-seq and WGBS to identify gene expression and methylation signatures that could highlight disease progression mechanisms.
  9. 9. Differential expression analysis 9 RNA-seq  Challenges:  Data-driven identification of clinical parameters that are indicative of disease progression  Differential expression analysis with very limited number of samples and high variability Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  10. 10. Methylation data generation and processing optimization BS-seq 10  Challenges:  Set up and optimise protocol(s) in the lab  Big strain on sequencing facilities and computational environment  Identification of appropriate analytical methods Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  11. 11. Target discovery
  12. 12. Genomic responses to viral infection RNA-seq + DNase-seq  Part of an ongoing collaboration with the University of Washington Department of Genome Sciences (Seattle, WA, USA).  Pilot study with primary cells from healthy volunteers infected with human rhinovirus.  Samples profiled by RNA-seq and DNase-seq to identify gene expression and regulatory chromatin responses to viral infection.  Identification and validation of pathways and targets for respiratory diseases with a strong infection component. Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  13. 13. Genomic responses to viral infection DNase-seq Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK  Challenges:  Differential analytical framework for DNase-seq data  Interpretation of biological signal from DNase hypersensitive sites
  14. 14. Drug MOA
  15. 15. Neurogenesis-inducing compounds MOA RNA-seq  Study to understand the mechanisms of action of two neurogenesis-inducing compounds and discriminate between the pathways they activate.  Neural progenitor cells profiled by RNA-seq to identify gene expression responses to the two compounds.  Identification of off-target effects and safety risks. Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  16. 16. Neurogenesis-inducing compounds MOA RNA-seq Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  17. 17. What else?
  18. 18. GSK partnerships with academic institutions Leveraging HTS technologies to improve the target discovery process Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  19. 19. Summary HTS technologies in the pharma industry  Making drugs is a very failure-prone business.  To increase our chances of success, we need to have better understanding of the biology of: – Our diseases; – Our targets; – Our drugs.  HTS assays such as RNA-seq, DNase-seq, ChIP-seq and WGBS are getting more and more widely used at GSK to support these activities.  Partnerships with CTTV and Altius are going to further increase the importance of HTS technologies throughout the target and drug discovery pipeline. Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK
  20. 20. Acknowledgements  Disease progression in rheumatoid arthritis (in collaboration with BTCURE and AMC) – Rab Prinjha (Epinova DPU, GSK) – Paul-Peter Tak (Immuno-inflammation TA, GSK) – Danielle Gerlag (Clinical Unit Cambridge, GSK) – Huw Lewis (Epinova DPU, GSK) – Erika Cule (Target Sciences, GSK) – Klio Maratou (Target Sciences, GSK) – George Royal (Target Sciences, GSK)  Neurogenesis-inducing compounds MOA – Hong Lin (Regenerative Medicine DPU, GSK) – Aaron Chuang (Regenerative Medicine DPU, GSK) – Julie Holder (Regenerative Medicine DPU, GSK) – Jing Zhao (Regenerative Medicine DPU, GSK) – Erika Cule (Target Sciences, GSK)  Genomic responses to viral infection (in collaboration with StamLab and UW) – Edith Hessel (Refractory Respiratory Inflammation DPU, GSK) – John Stamatoyannopoulos (StamLab, UW) – David Michalovich (Refractory Respiratory Inflammation DPU, GSK) – Soren Beinke (Refractory Respiratory Inflammation DPU, GSK) – Nikolai Belyaev (Refractory Respiratory Inflammation DPU, GSK) – Peter Sabo (StamLab, UW) – Eric Rynes (StamLab, UW) Applications of HTS technologies in the pharma industry Enrico Ferrero – Computational Biology @ GSK

×